SCHEDULE 13G 0001856083 XXXXXXXX LIVE Ordinary Shares, $0.0001 par value 01/06/2025 0001888886 Structure Therapeutics Inc. 86366E106 200 Greenwich Ave 3rd Floor Greenwich CT 06830 Rule 13d-1(c) Deep Track Capital, LP b DE 0.00 9000000.00 0.00 9000000.00 9000000.00 N 5.24 IA OO Deep Track Biotechnology Master Fund, Ltd. b E9 0.00 9000000.00 0.00 9000000.00 9000000.00 N 5.24 CO David Kroin b X1 0.00 9000000.00 0.00 9000000.00 9000000.00 N 5.24 HC IN Structure Therapeutics Inc. 601 Gateway Blvd., Suite 900, South San Francisco, CA 94080 (i) Deep Track Capital, LP (ii) Deep Track Biotechnology Master Fund, Ltd. (iii) David Kroin (i) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (ii) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands (iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (i) Delaware (ii) Cayman Islands (iii) United States Y 9,000,000 5.24 0 9,000,000 0 9,000,000 Y Y N Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person. Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Item 4: Information with respect to the Reporting Persons' ownership of the Common Stock as of January 13, 2025, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person. The amount beneficially owned by each Reporting Person is determined based on 171,782,018 Ordinary Shares outstanding as of October 31, 2024, according to the issuer's 10-Q filed with the SEC on November 13, 2024. Deep Track Capital LP, Deep Track Biotechnology Master Fund Ltd and David Kroin, together as the Reporting Persons', beneficially owns an aggregate of 9,000,000 ordinary shares of Structure Therapeutics Inc., consisting of 3,000,000 American Depositary Shares, each of which represents, and at the holder's option is convertible into, three ordinary shares. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: January 13, 2025 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin Deep Track Capital, LP David Kroin 01/13/2025 Deep Track Biotechnology Master Fund, Ltd. David Kroin 01/13/2025 David Kroin David Kroin 01/13/2025